UY36574A - Inhibidores de bromodominios - Google Patents

Inhibidores de bromodominios

Info

Publication number
UY36574A
UY36574A UY0001036574A UY36574A UY36574A UY 36574 A UY36574 A UY 36574A UY 0001036574 A UY0001036574 A UY 0001036574A UY 36574 A UY36574 A UY 36574A UY 36574 A UY36574 A UY 36574A
Authority
UY
Uruguay
Prior art keywords
bromodominium
inhibitors
compound
formula
salts
Prior art date
Application number
UY0001036574A
Other languages
English (en)
Inventor
Philip G Humphreys
Christopher Roland Wellaway
John Alexander Brown
Katherine Louise Jones
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of UY36574A publication Critical patent/UY36574A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención va destinada al compuesto de formula (I), que es 5-[1-(1,3- dimetoxipropan-2-il)-5-(morfolin-4-il)-1H-1,3-benzodiazol-2-il]-1,3-dimetil-1,2-dihidropiridin-2-ona:o una de sus sales, en particular una de sus sales farmacéuticamente aceptable. El compuesto de fórmula (I) se ha identificado como inhibidor de BET y, de este modo, tiene un potencial para su uso en terapia, por ejemplo, en el tratamiento de enfermedades inflamatorias y/o autoinmunitarias, tales como artritis reumatoide; y cánceres.
UY0001036574A 2015-03-05 2016-03-03 Inhibidores de bromodominios UY36574A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201503720A GB201503720D0 (en) 2015-03-05 2015-03-05 Chemical compound

Publications (1)

Publication Number Publication Date
UY36574A true UY36574A (es) 2016-09-30

Family

ID=52998420

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036574A UY36574A (es) 2015-03-05 2016-03-03 Inhibidores de bromodominios

Country Status (5)

Country Link
AR (1) AR103844A1 (es)
GB (1) GB201503720D0 (es)
TW (1) TW201704230A (es)
UY (1) UY36574A (es)
WO (1) WO2016139292A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180039117A (ko) 2015-08-11 2018-04-17 네오메드 인스티튜트 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CN108137539B (zh) 2015-08-12 2022-01-11 尼奥迈德研究所 取代的苯并咪唑、它们的制备和它们作为药物的用途
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
CN109280046B (zh) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 苯并咪唑类衍生物及其制备方法及其在医药上的用途
CN109384784B (zh) * 2017-08-10 2021-01-12 浙江海正药业股份有限公司 磺酰胺类衍生物、其制备方法及其在医药上的用途
WO2020219168A1 (en) * 2019-04-24 2020-10-29 Convergene, Llc Small molecule bromodomain inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones

Also Published As

Publication number Publication date
AR103844A1 (es) 2017-06-07
WO2016139292A1 (en) 2016-09-09
TW201704230A (zh) 2017-02-01
GB201503720D0 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
UY36574A (es) Inhibidores de bromodominios
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
ECSP20035588A (es) Derivado de amino-metil piperidina como inhibidor de quinasa
CO6870032A2 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
GT201400089A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY36153A (es) ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos?
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
UY36747A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221104